Obalon Therapeutics (OBLN) Stock Price, News & Analysis

Company Overview

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $2.35 to $2.44
• 50-Day Range: $2.36 to $7.64
• 52-Week Range: $0.66 to $10.77
• Volume: 76,819 shs
• Average Volume: 7.68 million shs
• Market Capitalization: $23.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OBLN Stock Analysis - Frequently Asked Questions

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.11. The business earned $0.06 million during the quarter. Obalon Therapeutics had a negative trailing twelve-month return on equity of 161.38% and a negative net margin of 776.76%.

When did Obalon Therapeutics' stock split?

Obalon Therapeutics's stock reverse split before market open on Thursday, July 25th 2019.The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Obalon Therapeutics IPO?

Obalon Therapeutics (OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Obalon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Canopy Growth (CGC), Plug Power (PLUG), NIO (NIO), NVIDIA (NVDA) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 3/11/2021
• Today: 7/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OBLN
• CIK: 1427570
• Web: www.obalon.com
• Phone: (844) 362-2566
• Fax: N/A
• Employees: 2
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.33 million
• Net Margins: -776.76%
• Pretax Margin: N/A
• Return on Equity: -161.38%
• Return on Assets: -83.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.86
• Quick Ratio: 1.86

Sales & Book Value

• Annual Sales: $1.59 million
• Price / Sales: 15.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: 4.03

Miscellaneous

• Outstanding Shares: 10,022,000
• Free Float: N/A
• Market Cap: $24.25 million
• Optionable: Not Optionable
• Beta: -1.23